WHO ICTRP trial
Transcatheter arterial chemoembolization (TACE) combined with adbelimumab and…
ChiCTR2300078210 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2300078210 |
|---|---|
| Public title | Transcatheter arterial chemoembolization (TACE) combined with adbelimumab and apatinib mesylate for advanced hepatocellular carcinoma was an open, single-center, prospective study |
| Scientific title | Transcatheter arterial chemoembolization (TACE) combined with adbelimumab and apatinib mesylate for advanced hepatocellular carcinoma was an open, single-center, prospective study |
| Primary sponsor | Jiangsu Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | hepatocellular carcinoma |
| Interventions | experimental group:TACE+ adbelimumab + apatinib mesylate |
| Registration date | Nov 30, 2023 |
| Target size | experimental group:20 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: